TTC17: A Potential Drug Target Or Biomarker (G55761)

Target Name: TTC17

NCBI ID: G55761

TTC17

TTC17: A Potential Drug Target Or Biomarker

Tetratricopeptide repeat domain 17 (TTC17) is a protein that is expressed in various tissues and organs, including the brain, heart, and liver. It is a repeat domain that is found in many proteins and is characterized by a specific sequence of amino acids. One of the unique features of TTC17 is that it has a highly conserved structure and is conserved in both humans and other organisms. This conservation has led to the hypothesis that TTC17 may be a drug target or biomarker.

The protein encoded by the TTC17 gene is a member of the superfamily of N-end rule RNA-binding proteins (SERPs). These proteins have a specific way of recognizing and interacting with specific RNA molecules. They do this by using a conserved motif called the N-end rule, which is a sequence of amino acids at the end of a RNA molecule that is specific for a particular RNA binding protein.

TTC17 is a 17-kDa protein that contains a single N-end rule motif. It is expressed in various tissues and organs and is highly conserved in both humans and other organisms. The conserved nature of TTC17 has led to the hypothesis that it may be a drug target or biomarker.

One of the potential reasons why TTC17 may be a drug target is its conserved nature. Many drugs work by binding to specific proteins and modulating their activity. If TTC17 is a drug target, then drugs that are able to bind to it and modulate its activity may be effective in treating various diseases. For example, TTC17 has been shown to be involved in the regulation of cellular processes that are important for brain development and function. Therefore, drugs that are able to modify TTC17 activity may be effective in treating conditions such as Alzheimer's disease, Parkinson's disease, and other neurological disorders.

Another potential reason why TTC17 may be a drug target is its involvement in the regulation of cellular processes that are important for overall health. Many diseases are caused by disruptions in the normal functioning of cells and tissues. TTC17 is involved in the regulation of cellular processes that are important for maintaining the health and integrity of tissues and organs. Therefore, drugs that are able to modulate TTC17 activity may be effective in treating a wide range of diseases.

In addition to its potential as a drug target, TTC17 may also be a biomarker. The conservation of TTC17 in various organisms has led to the hypothesis that it may be a conserved protein that is expressed in many different organisms. This suggests that TTC17 may be a useful biomarker for studying the effects of drugs on various organisms.

Furthermore, TTC17 has been shown to play a role in several cellular processes that are important for normal development and function. For example, TTC17 is involved in the regulation of cell adhesion, which is the process by which cells stick together to form tissues and organs. It is also involved in the regulation of cell signaling, which is the process by which cells communicate with each other to coordinate their activities.

In conclusion, TTC17 is a protein that is conserved in various organisms and has been shown to play a role in several cellular processes that are important for normal development and function. Its conserved nature and involvement in cellular processes that are important for overall health make it a potential drug target or biomarker. Further research is needed to determine the full extent of TTC17's role in these processes and to explore its potential as a drug or biomarker.

Protein Name: Tetratricopeptide Repeat Domain 17

Functions: Plays a role in primary ciliogenesis by modulating actin polymerization

The "TTC17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TTC17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets